Exact Sciences Corporation has announced pivotal clinical validation results from the ALTUS study (NCT: 05064553), evaluating the company's Oncoguard® Liver blood test for the early detection of hepatocellular carcinoma $(HCC)$, the most common form of liver cancer. The prospective, head-to-head trial demonstrated that the Oncoguard Liver test offers superior early-stage and overall sensitivity compared to the current standard of care. The test combines DNA methylation and protein markers to detect molecular signatures associated with liver cancer. According to Exact Sciences, the ALTUS study is the largest prospective, real-world trial of a blood test for liver cancer surveillance, and the results will be presented as late-breaking data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® on November 11, 2025. The company intends to submit the data for publication in a peer-reviewed journal.